

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 3, 2003 (Use as many sheets as necessary)		Complete if Known	
Application Number		08/981,583	
Filing Date		02/03/1998	
First Name of Inventor		Achim Dickmanns	
Group Art Unit		1642	
Examiner Name		Alana M. Harris	
Attorney Docket Number		028622-0101	

*FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
amh ↓	A1	DE	42 28 389	C2	Kubler et al.	07-21-1994	In German	
	A2	DE	43 22 570	C1	Thalmeier et al.	06-16-1994	Abstract only	
	A3	DE	44 22 570	C2	Gleich Patentinhaber	09-04-1997	In German	
	A4	EP	0 256 512	B1	Willecke et al.	09-31-1993	In German	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
amh	A5	Ariyoshi et al., "Biological and Clinical Implication of Neuron-Specific Enolase and Creatine Kinase BB in Small Cell Lung Cancer," <i>Jpn. J. Clin. Oncol.</i> 16(3):213-221 (1986).			
	A6	Chen et al., "Detection of Bone Marrow Micrometastasis," <i>Hybridoma</i> 18(5):465-466 (1999) © Mary Ann Liebert, Inc.			
	A7	Bartek et al., "Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus," <i>Proc. Natl. Acad. Sci USA</i> , 88:3520-3524 (May 1991) ©Cell Biology.			
amh	A8	Bepler et al., "Markers and characteristics of human SCLC cell lines," <i>J. Cancer Res. Clin. Oncol.</i> 113:253-259 (1987) ©Springer-Verlag.			
	A9	Bonfil et al., "Invasive and Metastatic Potential of a v-Ha-ras-Transformed Human Bronchial Epithelial Cell Line," <i>Journal of the National Cancer Institute</i> 81(8):587-594 (April 19, 1989)			
	A10	Carney et al., "Establishment and Identification of Small Cell Lung Cancer Cell Lines Having Classic and Variant Features," <i>Cancer Research</i> 45:2913-2923 (June 1985)			
	A11	Gazdar, Adi F. "The Molecular and Cellular Basis of Human Lung Cancer," <i>Anticancer Research</i> 13:261-268 (1994).			
	A12	Giaccone et al., "Neuromedin B Is Present in Lung Cancer Cell Lines," <i>Cancer Research</i> (Suppl) S2:2732s-2736s (May 1, 1992).			
	A13	Kraehenbuhl, J.P., "Dispersed Mammary Gland Epithelial Cells," <i>The Journal of Cell Biology</i> 72:390-405 (1977).			
	A14	Lebacqz-Verheyden, et al. "Posttranslational Processing of Endogenous and of Baculovirus-Expressed Human Gastrin-Releasing Peptide Precursor," <i>Molecular and Cellular Biology</i> , 8(8): 3129-3135 (Aug. 1988). © American Society for Microbiology.			

Examiner Signature	amh	Date Considered	2/12/2004
--------------------	-----	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 3, 2003 (Use as many sheets as necessary)		Complete if Known	
Application Number		08/981,583	
Filing Date		02/03/1998	
First Named Inventor		Achim Dickmanns	
Group Art Unit		1642	
Examiner Name		Alana M. Harris	
Attorney Docket Number		028622-0101	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
anh	A15	Minna et al., "Cancer of the Lung," <i>Cancer Principles & Practice of Oncology</i> , Fifth Edition, edited by DeVita et al., Chapter 30 pages 849-912 (1997)	
anh	A16	Mountain, M.D., Clifton F. "The New International Staging System for Lung Cancer," <i>Surgical Treatment of Lung Carcinoma</i> , 67(5): 925-935 (October 1987).	
anh	A17	Riquet et al., "Factors determining survival in resected N2 lung cancer," <i>Eur. J. Cardio-thorac Surg.</i> 9:300-304 (1995) © Springer-Verlag.	
	A18	Roth et al., "A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer," <i>Journal of the National Cancer Institute</i> 86(9): 673-680 (May 4, 1994)	
	A19	Shimosato, et al., "Biological, Pathological and Clinical Features of Small Cell Lung Cancer," <i>Cancer Letters</i> 33:241-258 (1986) © Elsevier Scientific Publishers Ireland Ltd.	
	A20	Thorban et al., "Disseminated Epithelial Tumor Cells in Bone Marrow of Patients with Esophageal Cancer: Detection and Prognostic Significance," <i>World Journal of Surgery</i> 20: 567-573 (1996) © Societe Internationale de Chirurgie.	
	A21	Yanagihara, et al., "A Radiation-induced Murine Ovarian Granulosa Cell Tumor Line: Introduction of v-ras Gene Potentiates a High Metastatic Ability," <i>Japan J. Cancer Res.</i> , 86:346-356 (April 1995)	

Examiner Signature	<i>Alana M. Harris</i>	Date Considered	2/12/2004
--------------------	------------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.